查看购物车
  • Traditional Chinese
  • English
  • Japanese
欧洲基因分型市场预测至 2031 年 - 区域分析 - 按产品类型、技术、应用和最终用户
市场调查报告书
商品编码
1666235

欧洲基因分型市场预测至 2031 年 - 区域分析 - 按产品类型、技术、应用和最终用户

Europe Genotyping Market Forecast to 2031 - Regional Analysis - by Product Type, Technology, Application, and End user
出版日期: | 出版商: The Insight Partners | 英文 156 Pages | 订单完成后即时交付

价格

2023 年欧洲基因分型市值为 87.299 亿美元，预计到 2031 年将达到 438.8343 亿美元；预计 2023 年至 2031 年的复合年增长率为 22.4%。

生物技术和製药行业的技术进步和研发投资的增加推动了欧洲基因分型市场的发展

基因分型市场参与者正致力于增加对旨在推动生物技术进步的计画的投资，以提供比传统技术更好的替代方案。

2024 年 1 月，赛默飞世尔科技推出 Axiom PangenomiX Array，为药物基因体学研究和群体规模疾病研究提供最佳基因覆盖。此阵列是目前唯一可以在一次测试中运行四种检测的研究解决方案：SNP 基因分型、完整基因组拷贝数变异检测、固定拷贝数发现以及血液和 HLA 分型。 2023 年 9 月，Bio-Rad 推出了用于定序、克隆和基因分型的新型 PTC Tempo 48/48 和 PTC Tempo 384 热循环仪。 PTC Tempo 热循环仪具有直觉的使用者介面和灵活的连接功能，可简化协定管理，并具有云端平台上的监控功能。 2023 年 1 月，Qiagen 收购了 Verogen，后者是一家利用次世代定序 (NGS) 技术推动法医调查和人类身分识别 (HID) 未来发展的公司。 QIAGEN 和 Verogen 有望共同创造机会，帮助研究人员推进法医科学，有助于准确识别嫌疑人、寻找失踪者并为无辜者洗脱罪名。 2022 年 6 月，NRGene 推出了 Soy SNPro，这是一款涵盖预先设计的 SNP 集的产品，用于各种作物的基因分型（DNA 测试）。 SNPro 是一种现成的完整基因分型解决方案，结合了低密度基因分型和高密度归因。 2022 年 5 月，NEOGEN 公司和 Gencove 宣布推出 InfiniSEEK，这是一种创新且经济高效的解决方案，可解决全基因组定序和有针对性的 SNP 分析所涉及的困难。这些技术突破有可能实现小型化、自动化和降低成本。它们还可以帮助提高操作灵活性和多参数测试。所有这些好处都增加了 DNA 定序的用途和便利性，使临床医生能够专注于更高层次的决策，例如透过各种基因分型研究选择和确定治疗目标的优先顺序。此外，NGS等DNA定序技术的进步使得定序速度更快、更准确，进而提高了生产效率。因此，日益增长的研究和开发活动以及政府对基因组计画的资助不断增加，促进了基因分型市场的进步。

欧洲基因分型市场概况

欧洲基因分型市场分为德国、英国、法国、义大利、西班牙和欧洲其他地区。该地区占据全球基因分型市场的第二大份额，预计在预测期内将实现显着的复合年增长率。技术进步、DNA定序程序价格降低、遗传疾病发生率增加以及个人化医疗意识增强等因素都是促进欧洲基因分型市场成长的因素。

欧洲基因分型市场收入及预测（2031 年）（百万美元）

欧洲基因分型市场细分

欧洲基因分型市场分为产品类型、技术、应用、最终用户和国家。

根据产品类型，欧洲基因分型市场分为仪器、试剂和试剂盒、生物资讯学和基因分型服务。试剂和试剂盒部分在 2023 年占据了最大的市场份额。

根据技术，欧洲基因分型市场细分为微阵列、毛细管电泳、定序、聚合酶链反应 (PCR)、基质辅助雷射解吸/MALDI-TOF 和其他技术。聚合酶链反应 (PCR) 领域在 2023 年占据了最大的市场份额。

根据应用，欧洲基因分型市场分为药物基因组学、诊断和个人化医疗、动物遗传学、农业生物技术和其他应用。 2023 年，诊断和个人化医疗领域占据最大的市场份额。

就最终用户而言，欧洲基因分型市场分为製药和生物製药公司、诊断和研究实验室、学术机构和其他最终用户。 2023 年，製药和生物製药公司部门占据了最大的市场份额。

依国家划分，欧洲基因分型市场分为英国、德国、法国、西班牙、义大利和欧洲其他地区。 2023 年，德国占据欧洲基因分型市场的主导份额。

Hoffmann-La Roche Ltd、QIAGEN NV、Merck KGaA、EUROFINS GENOMICS、Thermo Fisher Scientific Inc、BioTek Instruments Inc、Illumina Inc、Danaher Corp、Bio-Rad Laboratories Inc、GE HealthCare Technologies Inc、Standard BioTools Inc、Laboratory Corp of America、Sooratory Corp of。是欧洲基因分型市场的一些领导公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 关键见解

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 发育基数：
    • 数据三角测量：
    • 国家级资料：

第 4 章：欧洲基因分型市场格局

  • 概述
  • 全球市占率分析
    • NGS 文库製备主要参与者的全球市占率（%）
    • 基因分型领导企业的全球市场占有率（%）
    • 基因表现领域领导企业的全球市场占有率（%）

第 5 章：欧洲基因分型市场 - 主要市场动态

  • 市场驱动因素：
    • 用于诊断遗传疾病和罕见疾病
    • 生物技术和製药行业的技术进步和研发投资不断增加
  • 市场限制
    • 设备成本高，专业技术人员短缺
  • 市场机会
    • 扩大应用范围
  • 未来趋势
    • 个人化医疗日益普及
  • 驱动因素和限制因素的影响：

第 6 章：基因分型市场 - 欧洲分析

  • 2021 至 2031 年基因分型市场收入

第 7 章：欧洲基因分型市场分析 - 依产品类型

  • 仪器
  • 试剂和试剂盒
  • 生物资讯学
  • 基因分型服务

第 8 章：欧洲基因分型市场分析 - 按技术

  • 微阵列
  • 毛细管电泳
  • 定序
  • 聚合酶炼式反应（PCR）
  • 基质辅助雷射解吸/MALDI-TOF
  • 其他技术

第 9 章：欧洲基因分型市场分析 - 按应用

  • 药物基因组学
  • 诊断及个人化医疗
  • 动物遗传学
  • 农业生物技术
  • 其他应用

第 10 章：欧洲基因分型市场分析 - 按最终用户

  • 製药和生物製药公司
  • 诊断与研究实验室
  • 学术机构
  • 其他最终用户

第 11 章：欧洲基因分型市场 - 国家分析

    • 欧洲
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 义大利
      • 欧洲其他地区

第 12 章：产业格局

  • 概述
  • 基因分型市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 13 章：公司简介

  • Hoffmann-La Roche Ltd
  • QIAGEN NV
  • Merck KGaA
  • EUROFINS GENOMICS
  • Thermo Fisher Scientific Inc
  • BioTek Instruments, Inc.
  • Illumina Inc
  • Danaher Corp
  • Bio-Rad Laboratories Inc
  • GE HealthCare Technologies Inc
  • Standard BioTools Inc
  • Laboratory Corp of America Holdings
  • Beckman Coulter Inc
  • BGI
  • Takara Bio Inc
  • DiaSorin SpA

第 14 章：附录

Product Code: BMIRE00025969

The Europe genotyping market was valued at US$ 8,729.90 million in 2023 and is expected to reach US$ 43,883.43 million by 2031; it is estimated to record a CAGR of 22.4% from 2023 to 2031.

Technological Advancements and Rising R&D Investments in Biotechnology and Pharmaceutical Industry Drives Europe Genotyping Market

Genotyping market players are focusing on increasing their investments in projects aimed at advancements in biotechnology to come up with better alternatives to conventional techniques.

In January 2024, Thermo Fisher Scientific launched Axiom PangenomiX Array, offering optimal genetic coverage for pharmacogenomic research and population-scale disease studies. This array is currently the only research solution that can run four assays in one test: SNP genotyping, complete genome copies number variant detection, fixed copy number discovery, and blood and HLA typing. In September 2023, Bio-Rad launched new PTC Tempo 48/48 and PTC Tempo 384 thermal cyclers for sequencing, cloning, and genotyping. The PTC Tempo thermal cyclers are built with an intuitive user interface and flexible connectivity features to streamline protocol management, along with monitoring capabilities on the cloud platform. In January 2023, Qiagen acquired Verogen, a company that uses next-generation sequencing (NGS) techniques to drive the future of forensic investigation and human identification (HID). QIAGEN and Verogen together are expected to create opportunities to help researchers advance forensic science, thereby aiding accurate suspect identification, finding missing persons, and exonerating innocent individuals. In June 2022, NRGene launched Soy SNPro, a product covered under predesigned SNP sets for genotyping (DNA tests) of various crops. SNPro is an off-the-shelf complete genotyping solution that combines low-density genotyping with high-density imputation. In May 2022, NEOGEN Corporation and Gencove announced the launch of InfiniSEEK, an innovative and cost-effective solution for addressing difficulties involved in whole-genome sequencing and targeted SNP analyses. Such technological breakthroughs have the potential to enable miniaturization, automation, and cost reduction. They can also aid in operational flexibility and multiparameter testing. All these benefits add to the uses and convenience of DNA sequencing, allowing clinicians to concentrate on higher-level decisions such as selecting and prioritizing therapeutic targets through various genotyping studies. Further, technological advancements in DNA sequencing, such as NGS, have enabled speedy, accurate sequencing, allowing for great productivity. Thus, the growing research and development activities, along with increasing government funding for genome-based projects, contribute to the genotyping market progress.

Europe Genotyping Market Overview

The Europe genotyping market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds the second-largest share of the global genotyping market and is expected to register a notable CAGR during the forecast period. Factors such as technological advancements, reducing prices of DNA sequencing procedures, increasing incidence of genetic diseases, and rising awareness of personalized medicine are among the factors aiding the growth of the Europe genotyping market .

Europe Genotyping Market Revenue and Forecast to 2031 (US$ Million)

Europe Genotyping Market Segmentation

The Europe genotyping market is categorized into product type, technology, application, end user, and country.

Based on product type, the Europe genotyping market is segmented into instruments, reagents and kits, bioinformatics, and genotyping services. The reagents and kits segment held the largest market share in 2023.

By technology, the Europe genotyping market is segmented into microarrays, capillary electrophoresis, sequencing, polymerase chain reaction (PCR), matrix-assisted laser desorption / MALDI-TOF, and other technologies. The polymerase chain reaction (PCR) segment held the largest market share in 2023.

Based on application, the Europe genotyping market is bifurcated into pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and other applications. The diagnostics and personalized medicine segment held the largest market share in 2023.

In terms of end user, the Europe genotyping market is bifurcated into pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutes, and other end users. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2023.

By country, the Europe genotyping market is segmented into the UK, Germany, France, Spain, Italy, and the Rest of Europe. Germany dominated the Europe genotyping market share in 2023.

Hoffmann-La Roche Ltd, QIAGEN NV, Merck KGaA, EUROFINS GENOMICS, Thermo Fisher Scientific Inc, BioTek Instruments Inc, Illumina Inc, Danaher Corp, Bio-Rad Laboratories Inc, GE HealthCare Technologies Inc, Standard BioTools Inc, Laboratory Corp of America Holdings, Beckman Coulter Inc, BGI, Takara Bio Inc, and DiaSorin SpA. are some of the leading companies operating in the Europe genotyping market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Europe Genotyping Market Landscape

  • 4.1 Overview
  • 4.2 Global Market Share Analysis
    • 4.2.1 Global Market Share (%) of Leading Players for NGS Library Preparation
    • 4.2.2 Global Market Share (%) of Leading Player for Genotyping
    • 4.2.3 Global Market Share (%) of Leading Player for Gene Expression

5. Europe Genotyping Market - Key Market Dynamics

  • 5.1 Market Drivers:
    • 5.1.1 Use in Diagnosis of Genetic and Rare Diseases
    • 5.1.2 Technological Advancements and Rising R&D Investments in Biotechnology and Pharmaceutical Industry
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Equipment and Shortage of Skilled Professionals
  • 5.3 Market Opportunities
    • 5.3.1 Expanding Range of Applications
  • 5.4 Future Trends
    • 5.4.1 Increasing Popularity of Personalized Medicine
  • 5.5 Impact of Drivers and Restraints:

6. Genotyping Market - Europe Analysis

  • 6.1 Genotyping Market Revenue (US$ Million), 2021-2031

7. Europe Genotyping Market Analysis - by Product Type

  • 7.1 Instruments
    • 7.1.1 Overview
    • 7.1.2 Instruments: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Reagents and Kits
    • 7.2.1 Overview
    • 7.2.2 Reagents and Kits: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Bioinformatics
    • 7.3.1 Overview
    • 7.3.2 Bioinformatics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Genotyping Services
    • 7.4.1 Overview
    • 7.4.2 Genotyping Services: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Genotyping Market Analysis - by Technology

  • 8.1 Microarray
    • 8.1.1 Overview
    • 8.1.2 Microarray: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Capillary Electrophoresis
    • 8.2.1 Overview
    • 8.2.2 Capillary Electrophoresis: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Sequencing
    • 8.3.1 Overview
    • 8.3.2 Sequencing: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Polymerase Chain Reaction (PCR)
    • 8.4.1 Overview
    • 8.4.2 Polymerase Chain Reaction (PCR): Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Matrix-Assisted Laser Desorption / MALDI-TOF
    • 8.5.1 Overview
    • 8.5.2 Matrix-Assisted Laser Desorption / MALDI-TOF: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Other Technologies
    • 8.6.1 Overview
    • 8.6.2 Other Technologies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Genotyping Market Analysis - by Application

  • 9.1 Pharmacogenomics
    • 9.1.1 Overview
    • 9.1.2 Pharmacogenomics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Diagnostics and Personalized Medicine
    • 9.2.1 Overview
    • 9.2.2 Diagnostics and Personalized Medicine: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Animal Genetics
    • 9.3.1 Overview
    • 9.3.2 Animal Genetics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Agricultural Biotechnology
    • 9.4.1 Overview
    • 9.4.2 Agricultural Biotechnology: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.5 Other Applications
    • 9.5.1 Overview
    • 9.5.2 Other Applications: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

10. Europe Genotyping Market Analysis - by End-user

  • 10.1 Pharmaceutical and Biopharmaceutical Companies
    • 10.1.1 Overview
    • 10.1.2 Pharmaceutical and Biopharmaceutical Companies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Diagnostic and Research Laboratories
    • 10.2.1 Overview
    • 10.2.2 Diagnostic and Research Laboratories: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Academic Institutes
    • 10.3.1 Overview
    • 10.3.2 Academic Institutes: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.4 Other End Users
    • 10.4.1 Overview
    • 10.4.2 Other End Users: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)

11. Europe Genotyping Market - Country Analysis

  • 11.1 Europe Genotyping Market Overview
    • 11.1.1 Europe: Genotyping Market - Revenue and Forecast Analysis - by Country
      • 11.1.1.1 United Kingdom: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.1.1 United Kingdom: Genotyping Market Breakdown, by Product Type
        • 11.1.1.1.2 United Kingdom: Genotyping Market Breakdown, by Technology
        • 11.1.1.1.3 United Kingdom: Genotyping Market Breakdown, by Application
        • 11.1.1.1.4 United Kingdom: Genotyping Market Breakdown, by End-user
      • 11.1.1.2 Germany: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.2.1 Germany: Genotyping Market Breakdown, by Product Type
        • 11.1.1.2.2 Germany: Genotyping Market Breakdown, by Technology
        • 11.1.1.2.3 Germany: Genotyping Market Breakdown, by Application
        • 11.1.1.2.4 Germany: Genotyping Market Breakdown, by End-user
      • 11.1.1.3 France: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.3.1 France: Genotyping Market Breakdown, by Product Type
        • 11.1.1.3.2 France: Genotyping Market Breakdown, by Technology
        • 11.1.1.3.3 France: Genotyping Market Breakdown, by Application
        • 11.1.1.3.4 France: Genotyping Market Breakdown, by End-user
      • 11.1.1.4 Spain: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.4.1 Spain: Genotyping Market Breakdown, by Product Type
        • 11.1.1.4.2 Spain: Genotyping Market Breakdown, by Technology
        • 11.1.1.4.3 Spain: Genotyping Market Breakdown, by Application
        • 11.1.1.4.4 Spain: Genotyping Market Breakdown, by End-user
      • 11.1.1.5 Italy: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.5.1 Italy: Genotyping Market Breakdown, by Product Type
        • 11.1.1.5.2 Italy: Genotyping Market Breakdown, by Technology
        • 11.1.1.5.3 Italy: Genotyping Market Breakdown, by Application
        • 11.1.1.5.4 Italy: Genotyping Market Breakdown, by End-user
      • 11.1.1.6 Rest of Europe: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.1.6.1 Rest of Europe: Genotyping Market Breakdown, by Product Type
        • 11.1.1.6.2 Rest of Europe: Genotyping Market Breakdown, by Technology
        • 11.1.1.6.3 Rest of Europe: Genotyping Market Breakdown, by Application
        • 11.1.1.6.4 Rest of Europe: Genotyping Market Breakdown, by End-user

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Genotyping Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Hoffmann-La Roche Ltd
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 QIAGEN NV
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Merck KGaA
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 EUROFINS GENOMICS
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Thermo Fisher Scientific Inc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 BioTek Instruments, Inc.
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Illumina Inc
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Danaher Corp
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Bio-Rad Laboratories Inc
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 GE HealthCare Technologies Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Standard BioTools Inc
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments
  • 13.12 Laboratory Corp of America Holdings
    • 13.12.1 Key Facts
    • 13.12.2 Business Description
    • 13.12.3 Products and Services
    • 13.12.4 Financial Overview
    • 13.12.5 SWOT Analysis
    • 13.12.6 Key Developments
  • 13.13 Beckman Coulter Inc
    • 13.13.1 Key Facts
    • 13.13.2 Business Description
    • 13.13.3 Products and Services
    • 13.13.4 Financial Overview
    • 13.13.5 SWOT Analysis
    • 13.13.6 Key Developments
  • 13.14 BGI
    • 13.14.1 Key Facts
    • 13.14.2 Business Description
    • 13.14.3 Products and Services
    • 13.14.4 Financial Overview
    • 13.14.5 SWOT Analysis
    • 13.14.6 Key Developments
  • 13.15 Takara Bio Inc
    • 13.15.1 Key Facts
    • 13.15.2 Business Description
    • 13.15.3 Products and Services
    • 13.15.4 Financial Overview
    • 13.15.5 SWOT Analysis
    • 13.15.6 Key Developments
  • 13.16 DiaSorin SpA
    • 13.16.1 Key Facts
    • 13.16.2 Business Description
    • 13.16.3 Products and Services
    • 13.16.4 Financial Overview
    • 13.16.5 SWOT Analysis
    • 13.16.6 Key Developments

14. Appendix

  • 14.1 About Us
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. Europe Genotyping Market Segmentation
  • Table 2. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by Product Type
  • Table 3. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by Technology
  • Table 4. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by Application
  • Table 5. Genotyping Market - Revenue and Forecast to 2031 (US$ Million) - by End-user
  • Table 6. United Kingdom: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 7. United Kingdom: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 8. United Kingdom: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 9. United Kingdom: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 10. Germany: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 11. Germany: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 12. Germany: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 13. Germany: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 14. France: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 15. France: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 16. France: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 17. France: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 18. Spain: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 19. Spain: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 20. Spain: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 21. Spain: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 22. Italy: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 23. Italy: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 24. Italy: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 25. Italy: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 26. Rest of Europe: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Product Type
  • Table 27. Rest of Europe: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Technology
  • Table 28. Rest of Europe: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 29. Rest of Europe: Genotyping Market - Revenue and Forecast to 2031(US$ Million) - by End-user
  • Table 30. Recent Organic Growth Strategies in Genotyping Market
  • Table 31. Recent Inorganic Growth Strategies in the Genotyping Market
  • Table 32. Glossary of Terms, Genotyping Market

List Of Figures

  • Figure 1. Europe Genotyping Market Segmentation, by Country
  • Figure 2. Genotyping Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Genotyping Market Revenue (US$ Million), 2021-2031
  • Figure 5. Genotyping Market Share (%) - by Product Type (2023 and 2031)
  • Figure 6. Instruments: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Reagents and Kits: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Bioinformatics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Genotyping Services: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Genotyping Market Share (%) - by Technology (2023 and 2031)
  • Figure 11. Microarray: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Capillary Electrophoresis: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Sequencing: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Polymerase Chain Reaction (PCR): Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Matrix-Assisted Laser Desorption / MALDI-TOF: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Other Technologies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Genotyping Market Share (%) - by Application (2023 and 2031)
  • Figure 18. Pharmacogenomics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Diagnostics and Personalized Medicine: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Animal Genetics: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Agricultural Biotechnology: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Other Applications: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Genotyping Market Share (%) - by End-user (2023 and 2031)
  • Figure 24. Pharmaceutical and Biopharmaceutical Companies: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Diagnostic and Research Laboratories: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Academic Institutes: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Other End Users: Genotyping Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Europe Genotyping Market, by Key Countries - Revenue (2023) (US$ Million)
  • Figure 29. Europe: Genotyping Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 30. United Kingdom: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Germany: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. France: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Spain: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Italy: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 35. Rest of Europe: Genotyping Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 36. Growth Strategies in Genotyping Market